AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals ...

This was the stock's third consecutive day of losses.

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...